The cornerstone of biocatalysis lies in directed evolution, a method where scientists simulate natural selection in the lab by generating large libraries of enzymes with varied genetic sequences. These variants are then systematically screened to pinpoint those with the most desirable catalytic properties. While creating large, genetically diverse enzyme libraries is now routine, the Achilles’ heel of this process has consistently been the screening phase. Analyzing the molecular products made by thousands, sometimes tens of thousands, of enzyme candidates has historically been a painstakingly slow and resource-intensive bottleneck, delaying discovery timelines and inflating costs.

At the heart of the new approach is the enhancement of mass spectrometry, often referred to as “the world’s most expensive balance.” This analytical powerhouse measures the mass-to-charge ratio of molecules with remarkable precision, allowing scientists to deduce chemical compositions rapidly. However, traditional mass spectrometry struggles when confronted with molecules that share the exact molecular weight but differ in their three-dimensional spatial arrangements — a phenomenon known as chirality. These structural nuances, distinguishing mirror-image molecules akin to left and right hands, have profound implications in biology and pharmacology, where one isomer might be therapeutically beneficial while its counterpart could be inactive or even harmful.

The UC Santa Cruz researchers have devised a method that transcends this limitation by incorporating additional measurements that capture molecular shape and size. This hybrid analytical strategy empowers their platform to discriminate isomeric molecules efficiently, bypassing the need for time-consuming and cumbersome procedures previously required to differentiate chirality. Such capacity is pivotal when targeting natural products and pharmaceutical intermediates where structural specificity directly correlates with bioactivity and safety.

Their proof-of-concept application centers on kainic acid, a neuroactive compound naturally sourced from certain seaweed species. Kainic acid has long been valued in neuropharmacology for its selective activation of ionotropic glutamate receptors, which has made it an indispensable tool for studying neurological processes and diseases such as epilepsy. Traditionally, kainic acid was extracted directly from marine biomass, a process fraught with sustainability issues and supply constraints, exacerbated by overharvesting concerns that have previously threatened the ecological balance of those seaweed populations.

Synthetic chemistry has made numerous attempts to replicate kainic acid, with over seventy different synthetic routes documented. Unfortunately, despite this considerable effort, existing chemical syntheses remain lengthy, involving multiple reaction steps — often six to eleven in number — making scalable production both cumbersome and cost-prohibitive. This constrained access has limited kainic acid’s broader potential applications in research and therapeutic development.

Conversely, the enzymatic manufacturing pathway, initially pioneered by the Scripps Institution of Oceanography at UC San Diego and further refined at UC Santa Cruz, employs a remarkably efficient approach. This method begins with a chemically synthesized precursor, which is then converted into kainic acid through a single enzymatic reaction that effectively forms the molecule’s signature pyrrolidine ring system. Such biocatalytic efficiency reduces the synthesis timeline dramatically and opens doors to sustainable, large-scale production of kainoids and related neurochemicals.

A major contributor to this breakthrough is the synergistic collaboration between the Sanchez and McKinnie laboratories at UC Santa Cruz. The Sanchez Lab brought deep expertise in mass spectrometry and chemical analysis, while the McKinnie Lab contributed profound knowledge in enzyme discovery and organic synthesis. This interdisciplinary partnership facilitated the development of a screening paradigm that preserves and leverages three-dimensional structural information, enabling accurate distinction between molecular isomers during high-throughput screening assays.

Robert Shepherd, the principal graduate student leading this research, emphasizes the transformative nature of blending expertise across scientific domains to solve longstanding challenges in biocatalytic screening. He remarks on the invigorating research environment fostered by this collaborative effort, where convergence of diverse skills and perspectives catalyzes innovative solutions that transcend traditional disciplinary boundaries. This shared passion has fueled remarkable progress toward creating more potent, selective enzymes capable of synthesizing valuable compounds with reduced environmental footprints.

Beyond graduate students, the project enlisted the talents of postdoctoral fellows and undergraduates, with strong support from the Science Division’s STEM diversity programs. The team’s dedication was sustained by funding from the National Institutes of Health, via an R21 grant tailored to incentivize pioneering, high-impact research efforts still in early conceptual phases. This financial backing underscores the broader scientific community’s recognition of the potential impact that rapid and precise enzyme screening can have on drug discovery and green chemistry.

The promising platform outlined in this study sets a roadmap not only for accelerating enzyme evolution but also for democratizing access to powerful screening technologies, making them more accessible to a wide range of laboratories. By enabling researchers to swiftly navigate through vast enzyme variant libraries with improved accuracy and speed, the technology encourages deeper exploration of enzyme functions, paving the way for discovering novel catalysts and therapeutic agents.

In summary, the UC Santa Cruz team has delivered a technically sophisticated yet practically impactful tool that could reshape how chemists and biochemists approach the development of enzyme-driven synthesis. By surmounting longstanding obstacles in characterizing molecular isomers quickly and efficiently, this advancement significantly enhances the toolbox for biocatalysis and drug discovery. The marriage of advanced mass spectrometry with smart decision frameworks offers a powerful example of how innovation at disciplinary intersections can drive science forward with tangible societal benefits.

Article Title: A High-Throughput Biocatalytic Platform for Screening Isomeric Kainoid Natural Products
News Publication Date: 5-Feb-2026
Web References: https://www.cell.com/cell-reports-physical-science/fulltext/S2666-3864(25)00691-5
References: 10.1016/j.xcrp.2025.103092
Image Credits: By Carolyn Lagatutta, UC Santa Cruz

Keywords: biocatalysis, directed evolution, mass spectrometry, enzyme screening, chirality, kainic acid, neuropharmacology, high-throughput assay, enzyme variants, molecular isomers, sustainable synthesis, UC Santa Cruz

Traditionally, obtaining biological samples for proteomic analysis often required large volumes of blood or tissue, posing challenges in terms of invasiveness and the potential for sample degradation. The authors emphasize how microsampling techniques mitigate these issues by enabling protein analysis from tiny volumes of blood, such as a finger prick, which is less invasive and more patient-friendly. This approach not only reduces discomfort but also broadens the accessibility of proteomics in clinical settings.

The review highlights various microsampling methods, including dried blood spots (DBS) and filter paper techniques, which have gained traction in recent years. These techniques allow for the stable storage and transport of biological samples without the need for refrigeration, significantly improving the logistics of sample handling in clinical and field settings. By streamlining the process of sample collection, researchers can focus more on analysis and interpretation, paving the way for timely and informed clinical decisions.

One of the pivotal advantages of microsampling is the ability to utilize mass spectrometry, a technique renowned for its unparalleled sensitivity. The review discusses how modern mass spectrometric methods can detect low-abundance proteins in complex biological matrices, a feat that conventional proteomic techniques often struggle to achieve. By leveraging microsampling with advanced mass spectrometry, researchers can uncover novel biomarkers associated with various diseases earlier in their progression, ultimately leading to improved patient outcomes.

Furthermore, Campbell et al. delve into the implications of these advancements for personalized medicine. With the capacity to assess individual protein profiles from minute samples, clinicians can tailor treatments based on a patient’s specific biomarker landscape. This transition towards a more personalized approach marks a significant paradigm shift in how diseases are diagnosed and treated, fostering a proactive rather than reactive healthcare model.

The review also addresses some of the technical challenges associated with microsampling, such as the potential for bias in protein extraction and the need for meticulous standardization of protocols. The authors advocate for collaborative efforts in the scientific community to establish best practices and guidelines, thereby ensuring that the benefits of microsampling can be fully realized in diverse research and medical environments.

As the landscape of disease monitoring evolves, the integration of microsampling techniques also holds promise for population-level studies. By facilitating the collection of samples from larger groups with minimal discomfort, researchers can conduct extensive epidemiological studies that yield invaluable insights into disease trends and risk factors. This shift could play a crucial role in informing public health strategies and interventions.

Moreover, the review touches upon the ethical considerations of utilizing microsampling in research and clinical settings. Striking a balance between innovative advancements and ethical responsibilities is paramount, particularly in ensuring that patients understand the implications of such techniques and provide informed consent. As discussed, transparency and education will be key in fostering trust between researchers and the populations they serve.

In terms of regulatory frameworks, the authors note that as microsampling techniques gain traction, regulatory bodies will need to adapt existing guidelines to account for these novel methodologies. Clear regulations will not only safeguard patient safety but also support the continued advancement of research in this promising area.

The review concludes by envisioning a future where the integration of microsampling and mass spectrometry becomes standard practice in both research laboratories and clinical environments. By embracing these methodologies, the medical community can unlock the full potential of proteomics, ultimately leading to earlier disease detection, better patient management, and enhanced therapeutic outcomes.

In summary, Campbell et al. (2025) present a compelling case for the adoption of microsampling in mass spectrometry-based proteomics. By reducing the volume of biological samples required and improving the overall efficiency of biomarker discovery, this approach stands to revolutionize the field of personalized medicine and clinical diagnostics. As the groundwork laid in this review indicates, the future of proteomics is not just promising but transformative, with significant implications for healthcare worldwide.

Subject of Research: Microsampling in mass spectrometry-based proteomics

Article Title: From blood drops to biomarkers: a scoping review of microsampling in mass spectrometry-based proteomics.

Article References:

Campbell, A.J., Palstrøm, N.B., Rasmussen, L.M. et al. From blood drops to biomarkers: a scoping review of microsampling in mass spectrometry-based proteomics. Clin Proteom 22, 20 (2025). https://doi.org/10.1186/s12014-025-09540-w

Image Credits: AI Generated

DOI: 10.1186/s12014-025-09540-w

Keywords: microsampling, mass spectrometry, proteomics, biomarkers, clinical diagnostics, personalized medicine, dried blood spots, protein analysis